Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.
With long-read sequencing, mapping, and other approaches, researchers assembled a high-quality genome for Aedes aegypti, a notorious infectious disease vector.
Users expressed concern that Illumina would have an even tighter grip on the sequencing market but are optimistic that it would spur development of PacBio's technology.
Fresh off its August IPO, the company reported $2.8 million in revenue for the quarter, up from $2.7 million a year ago.
The VGP released its first 15 high-quality reference genome assemblies today, which are part of the project's first phase to sequence 260 vertebrate genomes.
Using Hi-C, genome sequencing, and optical mapping, researchers profiled structural variants in multiple cancer cell lines, leading to potential non-coding drivers.
The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.